Vakona Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
1
- Latest Deal Type
-
Later Stage VC
- Investors
-
7
Vakona General Information
Description
Developer of acne drugs designed to provide novel, efficient and antibiotic-free treatment for acne. The company develops drugs for acne, based on a protein from a skin bacterium that is normally found on our skin and can be used by applying skin cream by acne patients, enabling an effective treatment option for people suffering from acne problems.
Contact Information
Website
www.vakona.seCorporate Office
- Tvistevägen 48 C
- 907 36 Umeå
- Sweden
Corporate Office
- Tvistevägen 48 C
- 907 36 Umeå
- Sweden
Vakona Timeline
Vakona Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 28-Apr-2025 | Completed | Clinical Trials - Phase 1 | |||
| 4. Accelerator/Incubator | Completed | Product Development | ||||
| 3. Early Stage VC | 31-Oct-2023 | Completed | Product Development | |||
| 2. Early Stage VC | 29-Mar-2023 | $1.37M | $2.03M | Completed | Startup | |
| 1. Early Stage VC | 09-Nov-2021 | $662K | $662K | Completed | Startup |
Vakona Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 20,000 | $23.63 | $23.63 | 1x | $23.63 | 16.68% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Vakona Patents
Vakona Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020241178-A1 | New compositions and methods for the treatment of acne vulgaris | Active | 21-Mar-2019 | ||
| AU-2020241178-B2 | New compositions and methods for the treatment of acne vulgaris | Active | 21-Mar-2019 | ||
| CA-3133047-A1 | New compositions and methods for the treatment of acne vulgaris | Pending | 21-Mar-2019 | ||
| EP-3942030-A1 | New compositions and methods for the treatment of acne vulgaris | Pending | 21-Mar-2019 | ||
| EP-3942030-A4 | New compositions and methods for the treatment of acne vulgaris | Pending | 21-Mar-2019 | A61K38/465 |
Vakona Signals
Vakona Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Execa Allocation | Venture Capital | Minority | ||
| Almi Invest | Venture Capital | Minority | ||
| Partnerinvest Norr | Venture Capital | Minority | ||
| Phase2Phase Biopharma | Venture Capital | Minority |
Vakona FAQs
-
When was Vakona founded?
Vakona was founded in 2020.
-
Where is Vakona headquartered?
Vakona is headquartered in Umeå, Sweden.
-
What is the size of Vakona?
Vakona has 1 total employees.
-
What industry is Vakona in?
Vakona’s primary industry is Biotechnology.
-
Is Vakona a private or public company?
Vakona is a Private company.
-
What is Vakona’s current revenue?
The current revenue for Vakona is .
-
How much funding has Vakona raised over time?
Vakona has raised $4.83M.
-
Who are Vakona’s investors?
, Execa Allocation, Almi Invest, Partnerinvest Norr, and Phase2Phase Biopharma are 5 of 7 investors who have invested in Vakona.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process